Serologic Responses after Two Sequential Doses of Influenza A/New Jersey/76 Virus Vaccine in Normal Young Adults

The serologic responses after two sequential nonreactive doses of either chemically disrupted or whole-virus influenza A/New Jersey/76 virus vaccine were evaluated in 112 normal young adults. In general, levels of hemagglutination-inhibiting (HAl) antibody were low after the first dose of vaccine an...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1977-12, Vol.136 (Supplement-3), p.S496-S499
Main Authors: Wise, Thomas G., Dolin, Raphael, Mazur, Mark H., Ennis, Francis A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies
Antibodies, Viral - biosynthesis
B.Monovalent Vaccines in Adults
Clinical trials
Dosage
Dose-Response Relationship, Immunologic
Female
Hemagglutination Inhibition Tests
Humans
Influenza A virus - immunology
Influenza Vaccines - pharmacology
Male
New Jersey
Vaccination
Viral antigens
Virions
Virology
Viruses
Volunteerism
Young adults
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The serologic responses after two sequential nonreactive doses of either chemically disrupted or whole-virus influenza A/New Jersey/76 virus vaccine were evaluated in 112 normal young adults. In general, levels of hemagglutination-inhibiting (HAl) antibody were low after the first dose of vaccine and increased significantly (P < 0.05) in response to a second dose. Whereas one dose of the preparation from Merck Sharp and Dohme (West Point, Pa.) effectively vaccinated this population, two doses of the vaccines prepared by Parke, Davis and Company (Detroit, Mich.) and MerrellNational Laboratories (Cincinnati, Ohio) were required to produce a similar serologic response. The preparation from Wyeth Laboratories (Philadelphia, Pa.) produced low levels of HAl antibodies even after two doses. These different serologic responses correlated with the viral hemagglutinin content of each vaccine.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/136.Supplement_3.S496